Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 27 October 1995:
Vol. 270. no. 5236, pp. 575 - 577
DOI: 10.1126/science.270.5236.575
Prev | Table of Contents | Next

Research News

Trisha Gura

Antisense compounds once seemed the answer to drug designers' dreams: molecules precisely tailored to block specific genes. But researchers have run into unexpected difficulties, and they are no longer sure what antisense drugs are doing inside the body. Are clinical trials premature?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao (2002)
J. Thorac. Cardiovasc. Surg. 123, 1191-1198
   Abstract »    Full Text »    PDF »
Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes.
B.-J. Zeng, B.-C. Mortimer, I. J. Martins, U. Seydel, and T. G. Redgrave (1998)
J. Lipid Res. 39, 845-860
   Abstract »    Full Text »
Intracellular Distribution of Oligonucleotides Delivered by Cationic Liposomes: Light and Electron Microscopic Study.
K. Lappalainen, R. Miettinen, J. Kellokoski, I. Jaaskelainen, and S. Syrjanen (1997)
J. Histochem. Cytochem. 45, 265-274
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)